Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide and SBRT in Prostate Cancer (HEATWAVE)
NCT06067269Phase 2Recruiting
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of apalutamide in prostate adenocarcinoma, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Prostate Specific Antigen Complete Response Rate. Started Mar 2024; status: recruiting.
02
Drugs
apalutamide
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT06067269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06067269.